Dyax Kalbitor Is Third To Market For HAE, But First For All Acute Attacks
Overcoming an FDA advisory committee that expressed doubts about efficacy and potential hypersensitivity reactions and a "complete response" letter asking for a Risk Evaluation and Mitigation Strategy, Dyax won approval for Kalbitor (ecallantide) Nov. 27 to treat acute attacks of hereditary angioedema in patients 16 and older
You may also be interested in...
Different Endpoints Drive HAE Drugs On Road To Approval
With four drugs in the space, hereditary angioedema is an unusually well-served orphan disease. But the rare condition still has no clear path for efficacy assessment.
ViroPharma Could Manufacture Cinryze "At Risk" Starting Next Year
Delay in application for industrial scale production illustrates the challenges that biosimilar manufacturers will face.
FDA Advertising Enforcers Have Little Patience For "Well Tolerated" Drug Claims
Term is too vague for promotional use, regulators say, but it is not always cited as a violation, even when other aspects of the advertisement are.